drugset

drugset / Trial / NCT00866606

Study Evaluating On-Demand Treatment With BeneFIX In Chinese Subjects

NCT00866606 ↗

Phase 3 Completed 35 enrolled Wyeth is now a wholly owned subsidiary of Pfizer

Non-randomizedSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and efficacy of on-demand treatment with BeneFIX in Chinese hemophilia B subjects.

Timeline

Start: 2009-02
Primary completion: 2009-12
Completion: 2009-12

Publications

Yang R, Zhao Y, Wang X, Sun J, Jin J, Wu D, Charnigo R, O'Brien A, Zhong Z, Rendo P. Evaluation of the safety and efficacy of recombinant factor IX (nonacog alfa) in minimally treated and previously treated Chinese patients with haemophilia B. Haemophilia. 2012 Sep;18(5):e374-8. doi: 10.1111/j.1365-2516.2012.02907.x. Epub 2012 Jul 9. No abstract available.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	BeneFIX	Protein / enzyme biologic	75 iu/kg	Intravenous

Indications